On September 24, Viking Therapeutics fell 14.12% in regular trading, trading at approximately $35.96 per share, with turnover of $156 million. The decline was triggered by the company's announcement of separate public offerings totaling $400 million, comprising $200 million in common stock and $200 million in convertible senior notes due 2032.

The dual offering includes a 30-day overallotment option allowing underwriters to purchase up to an additional $30 million each of shares and notes. Net proceeds will fund clinical development and commercialization of VK2735 and VK3019 programs. The timing of the announcement amplified selling pressure, as it arrived on the heels of a dramatic two-day rally driven by positive maintenance study data for VK2735, the company's lead GLP-1/GIP dual agonist obesity candidate. On September 22, shares surged over 34% after data showed patients on biweekly dosing maintained up to 97% of weight loss, with monthly dosing preserving approximately 90%.

The equity dilution risk from the dual issuance, combined with profit-taking sentiment following the sharp run-up, drove the pronounced intraday pullback. Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)